NextEra Energy stock rises after Google power deal report
Natera, Inc. NASDAQ:NTRA Chief Financial Officer Michael Burkes Brophy sold 602 shares of common stock on October 21 at a price of $187.95, totaling $113145. The transaction comes as the $25.9 billion molecular diagnostics company trades near its 52-week high, with the stock showing impressive momentum, up 53% over the past year. According to InvestingPro analysis, Natera currently appears overvalued relative to its Fair Value.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction decreased Brophy’s direct ownership in Natera shares to 70109.
On October 20, Brophy also exercised 1522 Restricted Stock Units, which convert into common stock, in a transaction valued at $0.
In other recent news, Natera reported progress in its clinical trials and studies, highlighting its advancements in medical testing. The company has enrolled over 1,600 patients in its EXPAND trial, focusing on the Fetal Focus single gene noninvasive prenatal test for inherited conditions. This study aims to confirm test results through prenatal or postnatal diagnostic testing and involves a diverse, multi-ethnic population. Additionally, Natera’s Signatera test has shown promising results in monitoring uterine cancer recurrence and treatment response, as well as outperforming standard tumor markers in testicular cancer.
In terms of analyst actions, Canaccord Genuity maintained a Buy rating and a $200 price target on Natera, emphasizing its leadership in molecular residual disease testing. Wells Fargo resumed coverage with an Equal Weight rating and a $175 price target, highlighting Natera’s strong position in cell-free DNA testing technology. The company is also set to present 14 abstracts at the upcoming European Society for Medical Oncology Congress to reinforce its position in early cancer detection. These developments reflect Natera’s ongoing efforts to advance its testing capabilities and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.